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Background: The protective capacities of antibodies induced with Haemophilus influenzae type b (Hib) vaccines
can be directly assessed in vitro with a Hib-specific serum bactericidal assay (SBA). However, the conventional SBA
requires several tedious steps including manual counting of bacterial colonies, and therefore, it is seldom used.
Methods: To overcome these limitations, we have improved the conventional SBA by using frozen target bacteria
and by developing an automated colony counting method based on agar plates with the chromogenic dye
2, 3, 5-triphenyl tetrazolium chloride (TTC).
Results: These changes enabled us to analyze about 100 serum samples per day per person by SBA. When the
intra- and inter-assay precisions were studied, this assay showed a coefficient of variation (CV) ranging from 1 to
38 %. To monitor the long term assay stability for assays involving different bacteria lots, complement lots, and
operators, we analyzed bactericidal indices of quality control samples obtained over a 6 year period and found the
CV to be about 35–50 %. Lastly, our SBA results were compared with the ELISA results obtained using 90 serum
samples from children. We showed that the bactericidal index correlated with IgG anti-Hib antibody levels (r = 0.84),
with a bactericidal index of 10 corresponding approximately to 0.15 μg/mL IgG, the widely accepted protective
level of antibody.
Conclusion: We describe a simple high throughput SBA for anti-Hib antibodies that would be useful for evaluating
various Hib vaccines. While additional work will be needed to standardize the assay, this SBA should greatly
facilitate studies of Hib vaccines.
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Haemophilus influenzae type b (Hib) was the leading
cause of bacterial meningitis and a major cause of other
serious invasive diseases among children aged < 5 years
prior to the 1988 introduction of Hib conjugate vaccines
[1, 2]. Hib conjugate vaccines have been found to be very
safe and effective, and the use of the vaccines has reduced
both the incidence of Hib diseases and the carriage and
transmission of the organism in the community [2–5].
By 2013, Hib vaccines had been introduced into 189
countries [6].
To broadly deploy such a successful vaccine, substantial
effort has been also made to include the Hib vaccine as a
part of the combination vaccines [7]. Since different com-
ponents in the combination vaccines may interfere with
the Hib vaccine, these new Hib containing combination
vaccines require assessment of the Hib component of the
new vaccine formulation. To evaluate such combination
vaccines, there is a persistent need for an anti-Hib assay.
The cases of invasive Hib in children increased in the
United Kingdom when the Hib with diphtheria-tetanus-
whole-cell pertussis vaccine (DTwP) was replaced with a
diphtheria-tetanus-acellular pertussis (DTaP)-Hib vaccine.
In their 2009 study, Kelly et al. found a higher antibody
concentrations in children immunized in 1991 with Hib
with DTwP than in children immunized in the late 1990s
with DTaP-Hib [8]. Although the differences in the anti-
Hib antibody titers between the two groups may be partly
caused by reduced natural boosting opportunities after
high coverage of Hib vaccine or use of concomitant men-
ingococcal vaccine, this clearly demonstrated the need
for monitoring anti-Hib antibody concentrations in the
population in an active surveillance system. Moreover,
various factors including the type of vaccine, immunization
schedule, and ethnic differences could influence immune
responses [9]. Therefore, anti-Hib assays for evaluating
the immune response to Hib vaccines are required
constantly.
Although the levels of antibodies to Hib can be easily
measured with an enzyme-linked immunosorbent assay
(ELISA), an assay capable of measuring the protective cap-
acity of anti-Hib antibodies would be highly desirable.
Since the primary protective mechanism against gram
negative bacteria such as H. influenzae is antibody and
complement-mediated bactericidal killing, a good surro-
gate assay for immune protection induced by Hib vaccines
is an in vitro serum bactericidal assay (SBA) [10]. How-
ever, the conventional in vitro SBA is tedious to perform,
mainly because counting colonies is so time consuming.
Therefore, we have modified the conventional SBA by
automating colony counting and miniaturizing the bacte-
rial cultures required. Herein, we describe a new rapid
SBA, its assay performance characteristics, and the corre-
lation between the SBA and ELISA results.Methods
Serum samples
Four quality control (QC) sera with very high (QCVH),
high (QCH), medium (QCM), or low (QCL) titer sera pre-
pared by mixing sera from 2 to 3 individuals (age range =
26 to 42 years) and were previously described [11, 12].
Their reference ranges of anti-Hib antibody titer were
assigned after performing anti-Hib-antibody ELISA assay
for more than 50 times [11]. Their reference ranges (mean
± standard deviation [SD]) were 43.00 ± 6.54 μg/mL, 4.38
± 0.50 μg/mL, 1.52 ± 0.18 μg/mL, and 0.27 ± 0.07 μg/mL
for QCVH, QCH, QCM, and QCL, respectively [11]. These
sera were stored in 200-μL aliquots at −70 °C.
Ten pre-immune sera and 80 post-immune sera were
selected based on their serum availability from a cohort
of infants participating in an immunogenicity study of
the Hib vaccine in Korean infants [12]. Anti-Hib IgG
levels were previously determined for these residual sera
[12] and 0.15 μg/mL was used as the lower limit of assay
[11]. They were vaccinated with a single Hib vaccine
(PRP-T or PRP-OMP).
A high throughput SBA assay
SBA was performed as described [13] with modifications
described below. All serum samples were heated at 56 °C
for 30 min before testing was performed in duplicate. The
heat inactivated sera were serially (three fold) diluted
in a dilution buffer (Hanks’ buffer with Ca2+ and Mg2+
[Life Technologies, Grand Island, NY, USA] and 0.1 %
gelatin). A frozen aliquot of Hib Eagan strain [14] was
diluted in the dilution buffer to yield 750 colony forming
unit (CFU) in 10-μL. Twenty μl of diluted serum was
mixed with 10 μL of Hib solution and 10 μL of baby rabbit
complement (Pel-Freez Biologicals, Brown Deer, WI, USA)
in a microwell. The mixture was incubated for 2 min
at 25 °C with shaking at 700 rpm and incubated for
30 min at 37 °C in a CO2 incubator without shaking.
After stopping the reaction by placing the plates on ice for
15 min, 10 μL of the reaction mixture was plated on an
approximately 1 cm by 3 cm area of a brain-heart-
infusion (BHI) agar plate with 2 % Fildes enrichment
(Becton Dickinson and Company, Sparks, MD, USA).
After the fluid was absorbed into the agar, molten BHI
agar (0.75 %) with Fildes enrichment (2 %) and 25 mg/L
2, 3, 5-triphenyl tetrazolium chloride (TTC; Sigma, St.
Louis, MO, USA) was poured on top of the bottom agar
layer.
The plates were incubated at 37 °C in a 5 % CO2 incu-
bator for 16 h. Surviving bacterial colonies on the plates
were counted with NICE (NIST [National Institute of
Standards and Technology]’s Integrated Colony Enumer-
ator); a free software [15] available from Dr. J. Whang in
the US NIST) (http://www.nist.gov/pml/electromag-
netics/grp05/nice.cfm). The colony counts were used to
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a serum was defined as the dilution of the serum that
results in half as many colonies as are seen with comple-
ment controls. If an undiluted serum sample killed 50 %,
then the SBI is 4 in our system. To reduce the effect of
variable activation of the alternative pathway on SBI
result, each assay run included a complement control
containing bacteria and baby rabbit complement with no
serum. This complement control was used as 0 % killing
in the SBI calculation. A control serum was included in
each assay to monitor assay reproducibility. A detailed
SBA method is posted on the following website: http://
www.vaccine.uab.edu/.Reproducibility of SBA assays
The reproducibility of the Hib SBA was evaluated using
the four QC sera, QCVH, QCH, QCM, and QCL. To
determine intra-assay variability, sera were tested 5 times
in one assay run. To determine short-term inter-assay
variability, 11 independent assays using the same lot of
reagents were performed but on different days.
To determine the effect of varying assay components,
the assay was performed once with two different batches
of bacterial stock and once with two different batches of
complement. The overall mean ± SD and the coefficient
of variation (CV) of SBIs were calculated.
To assess long term assay performance, SBA was
performed with three QC sera (QCVH, QCH, and QCL)
over a 6 year period and their bactericidal indices were
plotted on a Levey-Jennings chart. During this period,
the assay involved four different lots of baby rabbit
complement, two different lots of Hib bacteria, and
three assay operators.Statistical analysis
Correlations between SBAs were determined by Pearson’s
correlation. Significant differences among assays were
determined by Student’s t test. Comparisons between
paired data were done by chi-square or Fisher’s two-tailed
exact test. The significance level was set at a P value of
<0.05.Fig. 1 Micro-colonies of Haemophilus influenzae type b on a BHI agar
plate with an agar overlay containing TTC. The average diameter of the
micro-colonies was about 0.3 mm and the red colonies were distinct
and could be readily counted with NICEEthics statement
The study protocol was approved by the Institutional
Review Board of Ewha Womans University Hospital. The
study was conducted in accordance with good clinical
practices (national regulations and ICH E6) and the
principles of the Helsinki Declaration. Informed written
consent was obtained from all participants or their parents
or legal guardians following a detailed explanation of the
study.Results
Establishment of the automated counting method
Automation of pneumococcal colony counting was
attempted using an overlay of agar containing TTC [16].
However, TTC can be toxic to some bacteria resulting in
the possibility that the overlay agar approach would not
be feasible. Additionally, the overlay agar approach could
have potentially failed because many bacteria may have
simply detached from the base agar and floated over the
overlay agar. Fortunately, Hib did not detach from the
base agar and the overlay agar approach was determined
to be feasible. To find a TTC concentration that gave opti-
mal color without toxicity, we next investigated the effects
of various concentrations (1–400 μg/mL) of TTC in the
overlay agar. We found that the best results were obtained
with 0.75 % agar containing 25 μg/mLTTC and 2 % Fildes
enrichment [10]. The number of colonies observed with
this overlay agar was equal to that of colonies observed
without the overlay, indicating that the selected concen-
tration of TTC was not toxic. With TTC, even very small
colonies with a diameter less than 1 mm were clearly
visible (Fig. 1), and allowed us to have up to 300 distinct
colonies in a 1 cm by 3 cm area of an agar plate. In a
conventional assay, a 96-well assay plate generates 96 agar
plates. However, in our new procedure, a petri dish can
have bacterial colonies from 48 reaction wells (i.e., half
of the 96 well plate). Consequently, this allowed us to
miniaturize the bacterial culture step and reduced the
number of agar plates used for the assay by 48-fold.
To efficiently count colonies on the agar plates using
the freely available program, NICE, we compared two
different methods for acquiring images of the bacterial
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be used to obtain the images and that the colony counts
obtained with digital camera images were highly corre-
lated (r = 0.96) with the true manual counts as previously
published [16], however, but the automated counts were
slightly lower (by about 10–15 %) than the true counts
(Fig. 2a). The deviation was noticeable when the number
of colonies per spot exceeded 50. We subsequently found
that images of four Petri dishes could be simultaneously
obtained using a document scanner (Scanjet G4010, HP
[Hewlett Packard Korea Ltd. Seoul, Korea]), which is read-
ily available in many offices [15], and that the counts
obtained with the scanner were highly correlated (r = 0.98)
with the true counts. The slope of the best fit line was
0.89, suggesting that the colony counts determined with
the scanner were slightly lower than the true counts.
Reproducibility of Hib SBA assays
Intra-assay and inter-assay variability
The intra-assay (within-assay) variability of SBA was
determined from 5 replicates of four QC sera performed
in one assay run (Table 1). The inter-assay (between
assays) variability of SBA was also determined on 11 runs
carried out on different days (Table 1). Their CVs ranged
9–38 % for intra-assay variability and 31–36 % for inter-
assay variability (Table 1). These CVs are comparable to
CVs of a Hib ELISA (KHK unpublished observation).
Long term assay variability
To investigate the long term reproducibility of SBA
results, we obtained results from assays using three QC
samples over a 6 year period (2006–2012) and plotted
their SBIs in a Levey-Jennings chart. During this period,
our SBA involved 2 different lots of target bacteria, 4 lotsFig. 2 The numbers of colonies per spot obtained using a digital camera (Pa
counts per spot (x-axis). The numbers of colonies were determined in 96 spot
indicate the best fit lines and their slopes were 0.84 and 0.89 for Panels a and
Panels a and b, respectively. The coefficient was 0.99 for data points with lessof complement, and 3 technicians. This chart therefore
reflects the realistic variability in assay results and demon-
strates that the SBA showed CVs ranging from 35 to 50 %
(Fig. 3).
Comparison of SBA with ELISA
As anti-Hib antibody ELISA has been extensively used in
studies of Hib vaccines and protective surrogates have
been established for Hib antibody ELISA, it was important
to compare our high throughput SBA results with the
ELISA results. The SBI and the anti-Hib IgG concentra-
tions are highly correlated (Fig. 4). The correlation coeffi-
cient (r) was 0.61 for the 80 post-immune sera and
became 0.84 when all 90 samples were included. For the
statistical analysis, it should be noted that we assigned
an SBI of 2 and an anti-Hib antibody concentration of
0.075 μg/mL to the 10 pre-immune samples (Fig. 4).
Interestingly, the 80 post-immune serum samples had
anti-Hib IgG concentrations of greater than 0.15 μg/mL
and, not surprisingly, all 80 samples had detectable
SBI. In contrast, the 10 pre-immune samples contained
0.15 μg/mL anti-Hib IgG and all of them resulted in
undetectable SBIs. Based on this data, we believe that
0.15 μg/mL and 1 μg/mL IgG anti-Hib antibody, the
widely accepted protective levels, may correspond to SBIs
of 10 and 64, respectively. Nevertheless, additional studies
would be necessary to establish the corresponding cut off
values.
Discussion
Herein we have described a high throughput SBA that is
easy to perform, requires no specialized equipment, and is
relatively robust. One reason we developed this SBA as a
high throughput was to accommodate the use of frozennel a) and a document scanner (Panel b) were compared with the true
s, and the true counts were established by manual counting. The lines
b, respectively. The correlation coefficients (r) were 0.96 and 0.98 for
than 100 CFU/spot in both panels
Table 1 Precision of serum bactericidal assay with four quality control sera
QCVH QCH QCM QCL
Serum bactericidal index
Intra-assay variability (N = 5) Mean 2876 1348 1865 824
Standard deviation 252 191 333 314
Coefficient of variation (%) 9 14 18 38
Range 2507 ~ 3072 1118 ~ 1532 1554 ~ 2336 510 ~ 1260
Inter-assay variability (N = 11) Mean 2841 1099 1017 637
Standard deviation 1016 344 331 216
Coefficient of variation (%) 36 31 33 34
Range 1582 ~ 4376 538 ~ 1623 492 ~ 1444 514 ~ 1095
N, number
Fig. 3 Levey-Jennings charts of serum bactericidal indices of three QC sera (a QCVH, b QCH, and c QCL) over 6 years. Runs 1–7 were performed
in 2006, runs 8–15 in 2009, runs 16 and 17 in 2011, and runs 18–20 in 2012. The two dotted and dashed lines in each panel indicate one and
two standard deviations (SDs) away from the mean, respectively
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Fig. 4 Comparison of SBA results with ELISA results. Ten sera with
undetectable anti-Hib IgG (closed circles) and 80 sera with≥ 0.15 μg/mL
anti-Hib IgG (open circles) were tested. The anti-Hib IgG concentration
(x axis) was compared with the serum bactericidal index, SBI (y axis).
The vertical dashed line drawn at a concentration of 0.15 μg/mL anti-Hib
IgG indicates the lower limit of the anti-Hib IgG ELISA and the horizontal
dashed line at an SBI of 4 indicates the lower limit of the SBA. The
vertical solid line drawn at a concentration of 1 μg/mL anti-Hib IgG
is shown for comparison. The 10 data points (closed circles) with
undetectable anti-Hib antibodies were assigned to have 0.075 μg/mL
and 2 SBI for the purpose of statistical calculation
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the target bacteria for each SBA experiment. Indeed,
frozen aliquots of S. pneumoniae have been used exten-
sively including for OPA. However, it was possible that
Hib would not survive the freeze/thaw cycles as well as
pneumococci do, since Gram negative bacteria are more
fragile than Gram positives. However, frozen Hib aliquots
were previously used for SBA by Romero-Steiner and col-
leagues [10] and we have also found that frozen aliquots
of Hib strains can be used in SBA with little difficulty.
Our experience should encourage the use of frozen
aliquots for assays using other Gram negative bacteria.
Indeed, we have found frozen bacteria can also be useful
for Shigella SBA (unpublished information).
The primary reason for achieving a high throughput is
the use of automated colony counting. Conventional SBAs
require manual counting of bacterial colonies, which is
tedious, time-consuming, and too labor-intensive for large
SBA runs. To automate the counting process, we suc-
cessfully adapted the simple overlay technique used for
pneumococci [16] to Hib. We also adapted NICE, an open
source program developed by the US NIST, to our SBA.
Although NICE was designed to use a digital camera, we
found a document scanner preferable because it did not
require focusing and was simpler to set up. This extrasimplicity has been highly useful to many investigators
performing bacterial colony counting for cholera [17] and
meningococci [18] cases.
Another major benefit of the overlay technique was
that it allowed for miniaturization of bacterial colonies
and a consequent reduction in the number of agar plates
used for the experiment. Since Hib is a human pathogen,
agar plates with Hib need to be autoclaved before they
are discarded. To analyze ~100 samples, about 2,000
agar plates would have been needed in the absence of
miniaturization and autoclaving 2,000 plates every day is
not a simple task. However, the overlay technique reduced
the necessary number of agar plates by 48-fold, reducing
the number plates that require autoclaving to roughly 50
plates per day. In fact, the reduction in the number of
plates needing to be autoclaved is another critical factor
required to achieve a high throughput.
Our SBA, in addition to its high throughput, demon-
strates stable analytical performance characteristics. It
showed intra- and inter-assay precisions that were com-
parable to those of a Hib ELISA. Particularly interesting
to us is that the SBIs of three QC sera obtained over 6
years showed CVs of 35–50 % in the absence of selection
of complement lots or many other rigorous controls and
standardization. Thus, while more rigorous evaluation of
this assay is necessary, we believe that our SBA is robust
and stable enough to be useful for vaccine studies.
In addition, we demonstrated that this high throughput
assay compares well with ELISA results. Interestingly, the
10 sera with anti-Hib IgG concentrations <0.15 μg/mL
resulted in undetectable SBIs whereas the 80 sera with
concentrations of ≥ 0.15 μg/mL showed detectable SBIs.
Our findings are consistent with the findings by Weinberg
GA, et al., who reported the minimal anti-Hib IgG anti-
body concentration required to kill 50 % of Hib in vitro to
be 0.22 μg/mL [19]. Taken together, we believe that SBA
can complement the existing anti-Hib IgG ELISA in con-
firming an adequate immune response to the Hib vaccine.
However, additional studies should be done to compare
SBA with ELISA using many more samples [20].Conclusions
We describe a simple and high throughput SBA for anti-
Hib antibodies that is easy to implement and practical
for studying various Hib vaccines. Pneumococcal vaccine
studies have clearly shown the importance of measuring
the function of pneumococcal antibodies [21, 22]. Since
ineffective anti-Hib antibodies exist [23, 24], an SBA
for Hib antibodies will be needed to study new Hib-
containing combination vaccines. While additional work
(e.g., standardization) needs to be performed to refine
our SBA, due to its simplicity and high throughput,
should be very useful for future Hib vaccine studies.
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